Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iBio (IBIO) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for iBio (IBIO) over the last 17 years, with Q4 2025 value amounting to $64.4 million.

  • iBio's Liabilities and Shareholders Equity rose 19678.3% to $64.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $170.8 million, marking a year-over-year increase of 3655.74%. This contributed to the annual value of $23.2 million for FY2025, which is 1931.16% down from last year.
  • As of Q4 2025, iBio's Liabilities and Shareholders Equity stood at $64.4 million, which was up 19678.3% from $64.2 million recorded in Q3 2025.
  • iBio's Liabilities and Shareholders Equity's 5-year high stood at $147.0 million during Q2 2021, with a 5-year trough of $19.1 million in Q1 2025.
  • Its 5-year average for Liabilities and Shareholders Equity is $68.2 million, with a median of $51.0 million in 2022.
  • As far as peak fluctuations go, iBio's Liabilities and Shareholders Equity surged by 23798.44% in 2021, and later tumbled by 6191.13% in 2025.
  • iBio's Liabilities and Shareholders Equity (Quarter) stood at $126.4 million in 2021, then crashed by 59.03% to $51.8 million in 2022, then crashed by 34.32% to $34.0 million in 2023, then tumbled by 36.23% to $21.7 million in 2024, then skyrocketed by 196.78% to $64.4 million in 2025.
  • Its Liabilities and Shareholders Equity was $64.4 million in Q4 2025, compared to $64.2 million in Q3 2025 and $23.2 million in Q2 2025.